The World Health Organization introduced a new class—near‑point‑of‑care nucleic acid amplification tests (nPOC‑NAATs)—designed for decentralized TB testing using swab specimens and simple workflows. Pluslife’s MiniDock MTB was announced as the sole member of the class after studies showed comparable yield to sputum testing. WHO’s guidance emphasizes ruggedized devices, enclosed reagents, and minimal operator steps to expand access in low‑resource and non‑laboratory settings. Pluslife is pursuing WHO prequalification and CE‑IVDR registration as countries consider adopting oral‑swab workflows to avoid sputum collection barriers.